{"id":1078,"date":"2023-02-14T13:54:30","date_gmt":"2023-02-14T13:54:30","guid":{"rendered":"https:\/\/oncologytweetorials-ce.com\/?p=1078"},"modified":"2023-02-15T13:24:15","modified_gmt":"2023-02-15T13:24:15","slug":"lungcancer_pro","status":"publish","type":"post","link":"https:\/\/oncologytweetorials-ce.com\/lungcancer_pro\/","title":{"rendered":"Patient-Reported Outcomes in Cancer Care"},"content":{"rendered":"\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">2) Our expert author is Thomas LeBlanc, MD <a href=\"https:\/\/twitter.com\/tomleblancMD?ref_src=twsrc%5Etfw\">@tomleblancMD<\/a>, patient experience &amp; cancer outcomes researcher <a href=\"https:\/\/twitter.com\/DukeCancer?ref_src=twsrc%5Etfw\">@DukeCancer<\/a>. Thanks for joining! <a href=\"https:\/\/t.co\/9lga8yCj76\">pic.twitter.com\/9lga8yCj76<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843475735347204?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">4) <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> in <a href=\"https:\/\/twitter.com\/hashtag\/mNSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#mNSCLC<\/a> were a hot topic at <a href=\"https:\/\/twitter.com\/hashtag\/ESMO22?src=hash&amp;ref_src=twsrc%5Etfw\">#ESMO22<\/a>. In prior discussions of the <a href=\"https:\/\/twitter.com\/hashtag\/POSEIDON?src=hash&amp;ref_src=twsrc%5Etfw\">#POSEIDON<\/a> trial, PRO data favored a triple combo of immunotherapy + chemotherapy over chemo alone, supporting the previously reported efficacy findings (\ud83d\udd13<a href=\"https:\/\/t.co\/aFOpRBCSrJ\">https:\/\/t.co\/aFOpRBCSrJ<\/a>). <a href=\"https:\/\/t.co\/xVAJzmpqIF\">pic.twitter.com\/xVAJzmpqIF<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843479069749248?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">6a) Patients are the experts on their own experiences. That\u2019s why we\u2019re talking today about \u201c<a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a>,\u201d short for \u201cpatient-reported outcome measures\u201d (sometimes abbreviated as <a href=\"https:\/\/twitter.com\/hashtag\/PROMs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROMs<\/a>). <br>See <a href=\"https:\/\/t.co\/dOqAE8i8HY\">https:\/\/t.co\/dOqAE8i8HY<\/a>. <a href=\"https:\/\/t.co\/PwhqpzFzIi\">pic.twitter.com\/PwhqpzFzIi<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843482362318849?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">7) Strictly defined, PROs are: \u201cdirect reports of patient experience that are usually collected via validated questionnaires without amendment or interpretation of the patient\u2019s response\u201d <br>See \ud83d\udd13 <a href=\"https:\/\/t.co\/FPNxi8EMvv\">https:\/\/t.co\/FPNxi8EMvv<\/a> from <a href=\"https:\/\/twitter.com\/HHSGov?ref_src=twsrc%5Etfw\">@HHSGov<\/a> and <a href=\"https:\/\/twitter.com\/US_FDA?ref_src=twsrc%5Etfw\">@US_FDA<\/a>.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843485826842624?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">9a) It comes as a surprise to some clinicians that subjective patient experiences can be measured and quantified in a meaningful way. In fact, patient experience data collected using high-quality <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> instruments are increasingly used as outcome measures in clinical trials.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843488880205824?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">10a) So WHY <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a>? And how good are they??<br>\ud83d\udc49Evidence clearly shows that clinicians under-estimate incidence &amp; severity of their patients\u2019 symptoms in routine care settings. <a href=\"https:\/\/t.co\/uyINxub5UK\">pic.twitter.com\/uyINxub5UK<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843498971811840?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">11) This recognition \u27a1\ufe0f various efforts to integrate <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a> into routine care processes in oncology, to effectively amplify \ud83d\udce2the patient voice.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843502599876609?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">13a) Modern <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> tools increasingly allow clinicians &amp; researchers to select individual items or create scales best suited to their local context &amp; a particular purpose. One prominent example are the <a href=\"https:\/\/twitter.com\/NIH?ref_src=twsrc%5Etfw\">@NIH<\/a>-developed \u201c<a href=\"https:\/\/twitter.com\/hashtag\/PROMIS?src=hash&amp;ref_src=twsrc%5Etfw\">#PROMIS<\/a>\u201d measures.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843507570114560?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">14a) So we have progressed to the point of moving beyond research and now applying <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a> to clinical practice. They aren&#8217;t just research tools w\/ rather unclear or limited applications to real-world clinical practice.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843510388588550?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">15a) Example: in <a href=\"https:\/\/twitter.com\/hashtag\/RCT?src=hash&amp;ref_src=twsrc%5Etfw\">#RCT<\/a> of 766 pts w\/advanced solid tumors on outpt palliative chemotx at <a href=\"https:\/\/twitter.com\/MSKCancerCenter?ref_src=twsrc%5Etfw\">@MSKCancerCenter<\/a>, weekly e-queries for symptom data \u27a1\ufe0fimprovements in <a href=\"https:\/\/twitter.com\/hashtag\/QoL?src=hash&amp;ref_src=twsrc%5Etfw\">#QoL<\/a>, \u2b07\ufe0fhealthcare utilization (ED use &amp; hospitalization), \u2b06\ufe0ftime on chemotx), &amp; overall survival, vs routine cancer care.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843519368699906?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">16) The symptom data reported by these pts were reviewed by nurses and acted upon accordingly. This trial clearly demonstrates the added value of collecting additional data on patients\u2019 experiences, directly from patients themselves, beyond what is done in routine care processes.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843522719866880?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">17b) The tool is called the <a href=\"https:\/\/twitter.com\/hashtag\/ESAS?src=hash&amp;ref_src=twsrc%5Etfw\">#ESAS<\/a> (Edmonton Symptom Assessment Scale\/System). In a retrospective study of data from over 250,000 pts w\/ cancer, a robust propensity-matching analysis showed that those who completed the ESAS at least once . . .<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625843525563678720?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">18a) Other studies point to value in collecting patient experience data using other approaches too, such as telephone-based interactive voice response (<a href=\"https:\/\/twitter.com\/hashtag\/IVR?src=hash&amp;ref_src=twsrc%5Etfw\">#IVR<\/a>) systems. These have the potential benefit of reducing disparities . . . <a href=\"https:\/\/t.co\/U9dksnOuwo\">pic.twitter.com\/U9dksnOuwo<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845295807401987?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19a) So can <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> assessments improve the patient experience of advanced cancer such as <a href=\"https:\/\/twitter.com\/hashtag\/mNSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#mNSCLC<\/a>?<br>As a matter of fact, as we\u2019ve learned more about how to measure the patient experience of cancer, the value of PROs has become clear.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845300609835008?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19c) In \ud83e\udec1 cancer especially, one proven intervention is integrated specialist <a href=\"https:\/\/twitter.com\/hashtag\/palliative?src=hash&amp;ref_src=twsrc%5Etfw\">#palliative<\/a> care. The efficacy of this approach was demonstrated largely on the basis of improvements in <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a>.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845304397295621?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">20) Overall survival was also improved among pts randomized to the palliative care intervention. Survival benefit among ambulatory patients with advanced solid cancers has been confirmed in multiple clinical trials &amp; meta-analyses<br>See \ud83d\udd13 <a href=\"https:\/\/t.co\/5s4iTwMsCV\">https:\/\/t.co\/5s4iTwMsCV<\/a> . <a href=\"https:\/\/t.co\/AoX84vlVMj\">pic.twitter.com\/AoX84vlVMj<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845308340031489?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">22a) The next big challenge in the story of <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a> is one of <a href=\"https:\/\/twitter.com\/hashtag\/implementation_science?src=hash&amp;ref_src=twsrc%5Etfw\">#implementation_science<\/a>. How can we deploy PROs efficiently and effectively in busy oncology practices of varying types? Many questions remain:<br>\u2753What PRO tool(s) are best? <a href=\"https:\/\/t.co\/ClBuIpfO33\">pic.twitter.com\/ClBuIpfO33<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845318053928960?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">22c)<br>\u2753What obligations arise upon collecting <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> data, regarding acting upon the results? <br>\u2753Do only certain cancer populations benefit from PRO monitoring (e.g. advanced cancers), or should all patients be offered PRO monitoring?<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845322034425856?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">23a) There are also related questions about other types of patient-generated health data that are now easily obtainable via fitness trackers or other connectivity-enabled devices, such as step counts, body composition, heart rate, weight, sleep duration\/quality, etc. <a href=\"https:\/\/t.co\/aZPdgy2Ubc\">pic.twitter.com\/aZPdgy2Ubc<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845337691721729?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">24a) One interesting example of such an effort is the Moovcare mobile application, which uses weekly symptom surveys to help detect \ud83e\udec1 cancer progression.<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845341856665600?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">25a) So as we \ud83c\udf81up, let&#8217;s return to those <a href=\"https:\/\/twitter.com\/hashtag\/mNSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#mNSCLC<\/a> data. Recently, 2 systematic reviews of Ph 3 <a href=\"https:\/\/twitter.com\/hashtag\/oncology?src=hash&amp;ref_src=twsrc%5Etfw\">#oncology<\/a> trials found that many solid tumor trials did not include <a href=\"https:\/\/twitter.com\/hashtag\/QoL?src=hash&amp;ref_src=twsrc%5Etfw\">#QoL<\/a> as an endpoint: <br>\ud83d\udd13 <a href=\"https:\/\/t.co\/i6Y3MiMMqi\">https:\/\/t.co\/i6Y3MiMMqi<\/a> <br>\ud83d\udd13 <a href=\"https:\/\/t.co\/aCW6cALplP\">https:\/\/t.co\/aCW6cALplP<\/a><\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845345732132865?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">25c) . . . looking back at you, <a href=\"https:\/\/twitter.com\/myESMO?ref_src=twsrc%5Etfw\">@myESMO<\/a>, incorporate <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> data into instruments developed to define the value of a treatment, such as the ESMO-Magnitude of Clinical Benefit Scale (<a href=\"https:\/\/t.co\/7QWlQuCC1B\">https:\/\/t.co\/7QWlQuCC1B<\/a>).<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845349377007617?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">26a) As a patient experience researcher and advocate, I am delighted to see the current emphasis on increasingly measuring and attending to these issues as part of holistic, person-centered cancer care. We have much more work left to do together though . . .<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845352921280513?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">27) So what have you learned? <a href=\"https:\/\/twitter.com\/hashtag\/PROs?src=hash&amp;ref_src=twsrc%5Etfw\">#PROs<\/a> may include all of the following EXCEPT:<br>a. measures of tolerance<br>b. measures of healthcare resource utilization<br>c. efficacy endpoints<br>d. symptom scales<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845356679364609?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">28b) The <a href=\"https:\/\/twitter.com\/hashtag\/ESMO_MCBS?src=hash&amp;ref_src=twsrc%5Etfw\">#ESMO_MCBS<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/PRO?src=hash&amp;ref_src=twsrc%5Etfw\">#PRO<\/a> instrument includes measures of all of the following EXCEPT:<br>a. overall survival<br>b. progression-free survival<br>c. healthcare resource utilization<br>d. response rate<\/p>\u2014 @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625845667775086594?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async=\"\" src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">30) And you just earned 0.5hr \ud83c\udd93CE\/CME! Go to <a href=\"https:\/\/t.co\/0YSCzsIHsZ\">https:\/\/t.co\/0YSCzsIHsZ<\/a> and claim your certificate. I am <a href=\"https:\/\/twitter.com\/tomleblancMD?ref_src=twsrc%5Etfw\">@tomleblancMD<\/a> and I \ud83d\ude4ffor joining us. FOLLOW <a href=\"https:\/\/twitter.com\/onc_ce?ref_src=twsrc%5Etfw\">@onc_ce<\/a> for more expert-authored education, delivered entirely on Twitter!<a href=\"https:\/\/twitter.com\/hashtag\/FOAMed?src=hash&amp;ref_src=twsrc%5Etfw\">#FOAMed<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/OncTwitter?src=hash&amp;ref_src=twsrc%5Etfw\">#OncTwitter<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/MedEd?src=hash&amp;ref_src=twsrc%5Etfw\">#MedEd<\/a> <a href=\"https:\/\/twitter.com\/MedTweetorials?ref_src=twsrc%5Etfw\">@MedTweetorials<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1625848058373361666?ref_src=twsrc%5Etfw\">February 15, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<iframe id=\"JotFormIFrame-230443301132134\" title=\"lungcancer_PRO | Oncology CE 2023new\" onload=\"window.parent.scrollTo(0,0)\" allowtransparency=\"true\" allowfullscreen=\"true\" allow=\"geolocation; microphone; camera\" src=\"https:\/\/form.jotform.com\/230443301132134\" frameborder=\"0\" style=\"min-width:100%;max-width:100%;height:1539px;border:none;\" scrolling=\"no\">\n    <\/iframe>\n    <script type=\"text\/javascript\">\n    var ifr = document.getElementById(\"JotFormIFrame-230443301132134\");\n    if (ifr) {\n      var src = ifr.src;\n      var iframeParams = [];\n      if (window.location.href && window.location.href.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(window.location.href.substr(window.location.href.indexOf(\"?\") + 1).split('&'));\n      }\n      if (src && src.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(src.substr(src.indexOf(\"?\") + 1).split(\"&\"));\n        src = src.substr(0, src.indexOf(\"?\"))\n      }\n      iframeParams.push(\"isIframeEmbed=1\");\n      ifr.src = src + \"?\" + iframeParams.join('&');\n    }\n    window.handleIFrameMessage = function(e) {\n      if (typeof e.data === 'object') { return; }\n      var args = e.data.split(\":\");\n      if (args.length > 2) { iframe = document.getElementById(\"JotFormIFrame-\" + args[(args.length - 1)]); } else { iframe = document.getElementById(\"JotFormIFrame\"); }\n      if (!iframe) { return; }\n      switch (args[0]) {\n        case \"scrollIntoView\":\n          iframe.scrollIntoView();\n          break;\n        case \"setHeight\":\n          iframe.style.height = args[1] + \"px\";\n          if (!isNaN(args[1]) && parseInt(iframe.style.minHeight) > parseInt(args[1])) {\n            iframe.style.minHeight = args[1] + \"px\";\n          }\n          break;\n        case \"collapseErrorPage\":\n          if (iframe.clientHeight > window.innerHeight) {\n            iframe.style.height = window.innerHeight + \"px\";\n          }\n          break;\n        case \"reloadPage\":\n          window.location.reload();\n          break;\n        case \"loadScript\":\n          if( !window.isPermitted(e.origin, ['jotform.com', 'jotform.pro']) ) { break; }\n          var src = args[1];\n          if (args.length > 3) {\n              src = args[1] + ':' + args[2];\n          }\n          var script = document.createElement('script');\n          script.src = src;\n          script.type = 'text\/javascript';\n          document.body.appendChild(script);\n          break;\n        case \"exitFullscreen\":\n          if      (window.document.exitFullscreen)        window.document.exitFullscreen();\n          else if (window.document.mozCancelFullScreen)   window.document.mozCancelFullScreen();\n          else if (window.document.mozCancelFullscreen)   window.document.mozCancelFullScreen();\n          else if (window.document.webkitExitFullscreen)  window.document.webkitExitFullscreen();\n          else if (window.document.msExitFullscreen)      window.document.msExitFullscreen();\n          break;\n      }\n      var isJotForm = (e.origin.indexOf(\"jotform\") > -1) ? true : false;\n      if(isJotForm && \"contentWindow\" in iframe && \"postMessage\" in iframe.contentWindow) {\n        var urls = {\"docurl\":encodeURIComponent(document.URL),\"referrer\":encodeURIComponent(document.referrer)};\n        iframe.contentWindow.postMessage(JSON.stringify({\"type\":\"urls\",\"value\":urls}), \"*\");\n      }\n    };\n    window.isPermitted = function(originUrl, whitelisted_domains) {\n      var url = document.createElement('a');\n      url.href = originUrl;\n      var hostname = url.hostname;\n      var result = false;\n      if( typeof hostname !== 'undefined' ) {\n        whitelisted_domains.forEach(function(element) {\n            if( hostname.slice((-1 * element.length - 1)) === '.'.concat(element) ||  hostname === element ) {\n                result = true;\n            }\n        });\n        return result;\n      }\n    };\n    if (window.addEventListener) {\n      window.addEventListener(\"message\", handleIFrameMessage, false);\n    } else if (window.attachEvent) {\n      window.attachEvent(\"onmessage\", handleIFrameMessage);\n    }\n    <\/script>\n","protected":false},"excerpt":{"rendered":"<p>2) Our expert author is Thomas LeBlanc, MD @tomleblancMD, patient experience &amp; cancer outcomes researcher @DukeCancer. Thanks for joining! pic.twitter.com\/9lga8yCj76 \u2014 @onc_ce (@onc_ce) February 15, 2023 4) #PRO in #mNSCLC were a hot topic at #ESMO22. In prior discussions of the #POSEIDON trial, PRO data favored a triple combo of immunotherapy + chemotherapy over chemo [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_mi_skip_tracking":false,"footnotes":""},"categories":[22],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1078"}],"collection":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/comments?post=1078"}],"version-history":[{"count":3,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1078\/revisions"}],"predecessor-version":[{"id":1082,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1078\/revisions\/1082"}],"wp:attachment":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/media?parent=1078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/categories?post=1078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/tags?post=1078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}